John Sweetenham, MD, PhD

Editorials by John Sweetenham, MD

Editorial

Putting the CAR Ts before the horse

HemOnc Today, January 10, 2018
John Sweetenham, MD
The daily flood of sponsored and nonsponsored content often reports the same studies, new FDA approvals, latest meetings and so on with such a degree…
Editorial

Tobacco, alcohol and cancer: Not always black and white

HemOnc Today, December 10, 2017
John Sweetenham, MD
The mother of a friend and former colleague of mine was recently admitted to our facility for evaluation of a lung mass. An initial biopsy indicated…
Editorial

The preservation of affordable cancer care

HemOnc Today, November 10, 2017
John Sweetenham, MD
In a 6-month period characterized by political chaos, there have been plenty of reasons to become disheartened by the apparent lack of dialogue…
Editorial

Physical activity and cancer outcomes: Growing evidence for the oncologist

HemOnc Today, October 10, 2017
John Sweetenham, MD
I have been running regularly throughout most of my adult life, beginning at school, through medical school and to the present day. My runs have…
Editorial

The pathway to value: A complicated journey begins with one step

HemOnc Today, September 10, 2017
John Sweetenham, MD
The intensity of coverage of drug costs and value in oncology care in peer-reviewed journals, the popular oncology press, the media in general and…
Editorial

Stem cell transplantation and CMS: Extreme (hospital at) home makeover

HemOnc Today, August 10, 2017
John Sweetenham, MD
“It’s no wonder that truth is stranger than fiction. Fiction has to make sense.” – Mark Twain
Editorial

‘Port-alisib’ and ‘reach-out-to-me-mab’: A novel combination extends OS in a range of cancer types

HemOnc Today, July 10, 2017
John Sweetenham, MD, FRCP, FACP
Before you Google this combination to figure out how you missed the presentation at the ASCO Annual Meeting, please read on. I do not want you to…
Editorial

‘Special focus’ required to eliminate disparities among millennials with cancer

HemOnc Today, June 10, 2017
John Sweetenham, MD
Last week was a first for me — I participated in a Facebook live event. I had no idea what to expect, but a group of very smart — and…
Editorial

Healthy — and not so healthy — competition

HemOnc Today, May 10, 2017
John Sweetenham, MD
ASCO published its annual report on the state of cancer care in America earlier this spring. As in previous years, the report highlights significant…
Editorial

The cost of living: Financial constraints put benefits of revolutionary treatments at risk

HemOnc Today, April 10, 2017
John Sweetenham, MD
In early March, long-term follow up results of the IRIS trial appeared in The New England Journal of Medicine. This study, opened in 2000, compared…